| Dr Jeffrey Irving Menashe, MD | |
|
5050 Ne Hoyt St, Ste 256, Portland, OR 97213-2982 | |
| (503) 239-7767 | |
| (503) 215-6897 |
| Full Name | Dr Jeffrey Irving Menashe |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 5050 Ne Hoyt St, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871596551 | NPI | - | NPPES |
| 1021098 | Medicaid | WA | |
| 081083 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD15990 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Irving Menashe, MD 5050 Ne Hoyt St, Ste 256, Portland, OR 97213-2982 Ph: (503) 239-7767 | Dr Jeffrey Irving Menashe, MD 5050 Ne Hoyt St, Ste 256, Portland, OR 97213-2982 Ph: (503) 239-7767 |
News Archive
Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The discovery will likely help physicians decide how closely to monitor men potentially at risk for the cancer - among the most confusing and controversial dilemmas in health care.
Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.
Chemotherapy after surgery more than doubles survival rates for pancreatic cancer according to new research published today (18 March 2004) in the New England Journal of Medicine. Scientists from the University of Birmingham and the University of Liverpool have carried out a Europe wide study of more than 280 patients over 10 years.
During hysterectomy operations, surgeons often remove a woman's ovaries as well as her uterus. Cochrane Researchers now say there is no evidence that removing the ovaries provides any additional benefit and warn surgeons to consider the procedure carefully.
› Verified 2 days ago
Salona Shrestha, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |